MBDB (N-methyl-1,3-benzodioxolylbutanamine) is a structural analog of MDMA, differing only by the substitution of an ethyl group in the place of the methyl group at the carbon.
Introduction to MBDB
First synthesised by David E. Nichols, MBDB falls into the family of phenethylamines, acting as a strong entactogen with effects similar to but not identical to that of MDMA. MBDB has IC50 values of 784 nM for 5-HT, 7825 nM for dopamine, and 1233 nM for norepinephrine. While MBDB was initially developed as a non-psychedelic entactogen, it tends to show some of the psychedelic effects which are seen with MDMA, thus for this reason MBDB has been dubbed a watered down version of MDMA. Compared to MDMA and other entactogens, MBDB has a lesser effect on the dopamine systems. This may make it less suitable for recreation while still being useful for therapeutic purposes.
Using MBDB
Ways of Administration
Similar to MDMA, the effects of MBDB are best achieved when the compound is consumed through oral administration, this is due most likely to the high concentration of 5-HT serotonin receptors which line the walls of the gastrointestinal tract.Effects of MBDB
Positive
- Lowering of social barriers
- Empathy & compassion
- Mood Lift
- Mild euphoria
- Lethargy
- Sedation
- Mild stimulation
Neutral
- Nystagmus
- Open and closed eye hallucinations
Negative
- Dysphoria
- Insomnia
- Elevated body temperature
- Anxiety
- Paranoia
Chemistry of MBDB
Column 1 Column 2 Systematic(IUPAC) name: (RS)-1-(1,3-Benzodioxol-5-yl)-N-methylbutan-2-amine Synonyms: MBDB, N-Methyl-1,3-Benzodioxolylbutanamine Molecular Formula: C12H17NO2 Molar mass: 207.27 g/mol [1] CAS Registry Number: 103818-46-8 Melting Point: 156 °C Boiling Point: Flash Point: Solubility: Additionnal data: Notes:
The Dangers of MBDB
As with any psychoactive substance there are several dangers which are associated with MBDB that should not be overlooked by a user who intends to consume this compound...
- MBDB is a research chemical, thus there is limited information on its effects and side effects as there have been minimal to no formal studies conducted on this compound.
- MBDB acts on the serotonin receptors, thus additional serotonergics and MAOIs should be avoided as there is a chance for serotonin syndrome to occur is combined.
- MBDB is a psychoactive substance with some mild stimulating effects, it should be avoided by users who have a known mental or physical illness as the drug may exacerbate these symptoms.
Legal Status of MBDB
United Nations
USA
MBDB is currently unscheduled in the United States, however individual state laws may differ.
In Florida, MBDB is listed as a Schedule I Controlled Substance.EU
Other Countries
Austria
MBDB is a controlled substance in the country of Austria.Japan
As of April, 2005 MBDB is considered to be a controlled substance in the country of Japan.Norway
MBDB is listed as a controlled substance under the Derivatbestemmelsen (Analog Law).Slovak Republic
As of March 1, 2011 MBDB is considered a controlled substance in the Slovak Republic.Sweden
As of April 1, 1999 MBDB is listed as a controlled substance under Swedens "Compounds Dangerous to Ones Health Law".
MBDB